



Business Results

First Six Months of the

Fiscal Year Ending March 31, 2025

Sysmex Corporation
November 6, 2024

Together for a better
healthcare journey

Disclaimer

- This material contains forward-looking statements about the Sysmex Group. These forward-looking statements are based on the current judgments and assumptions of the Sysmex Group in light of the information currently available to it. Uncertainties inherent in such judgments and assumptions, the future course of our business operations and changes in operating environments both in Japan and overseas may cause our actual results, performance, achievements, or financial position to be materially different from any future results, performance, achievements or financial position either expressed or implied within these forward-looking statements.
- The information on products and other matters contained herein is not intended as advertising or medical advice, whether or not regulatory approval has been obtained.
- The Sysmex Group adopted International Financial Reporting Standards (IFRS) in the fiscal year ended March 31, 2017. Figures are disclosed in compliance with IFRS.
- In the fiscal year ended March 31, 2022, the Sysmex Group changed its method of recognizing the costs of configuration or customization services in cloud computing contracts as an expense when these services are received.

Index

- 1. Executive Summary**
- 2. Business Results, First Six Months of the Fiscal Year Ending March 31, 2025**
- 3. Growth Strategy Progress and Initiatives**
- 4. Financial Forecast for the Fiscal Year Ending March 31, 2025**

(Appendix)

- Q2 Business Results (Year on Year)
- Sales Forecast for the Fiscal Year Ending March 31, 2025 (by Business, Field and Destination)
- Publication of *Sysmex Report 2024* and the *Sysmex Sustainability Data Book 2024*

1. Executive Summary

Results for the First Six Months of the Fiscal Year Ending March 31, 2025

Net sales and operating profit increased significantly. Net sales, operating profit, and profit attributable to owners of the parent all reached record highs.

Year on year: Net sales +14.0%, operating profit +31.6%, profit attributable to owners of the parent +17.2%

- Owing to higher reagent sales and taking emerging markets as opportunities for growth, business was favorable, with sales increasing in all regions.
- Owing to the product mix and cost reductions, the cost of sales ratio improved, leading substantially higher operating profit.

Financial Forecast for the Fiscal Year Ending March 31, 2025

We revised our operating profit forecast upward by ¥3.0 billion, to ¥90.0 billion for the full fiscal year. With our measures progressing smoothly, we anticipate ongoing growth globally.

- Improvements in the cost of sales ratio owing to higher reagent sales
- Increased sales in the hemostasis field in Europe and North America, and an ongoing contribution from expected growth in emerging markets
- Continuing to invest toward the next stage, such as in internal digitalization, new product development, and fundamental research

2.


**Business Results, First Six Months of the
Fiscal Year Ending March 31, 2025**

Financial Highlights (Year on Year)



(Billions of yen)	First six months of fiscal year ending March 31, 2025		First six months of fiscal year ended March 31, 2024		YoY (Previous period = 100%)
	Results	Ratio	Results	Ratio	
Net sales	242.4	100%	212.6	100%	114.0%
Cost of sales	111.1	45.9%	101.6	47.8%	109.3%
SG&A expenses	72.3	29.8%	62.5	29.4%	115.6%
R&D expenses	15.2	6.3%	15.0	7.1%	101.5%
Other income (expenses)	0.8	0.3%	0.4	0.2%	197.2%
Operating profit	44.5	18.4%	33.8	15.9%	131.6%
Profit attributable to owners of the parent	26.0	10.7%	22.1	10.4%	117.2%


- **Net sales:** Net sales reached record high. Sales were up in all regions, buoyed by favorable results for the XR™-Series, robust reagent sales and increased sales in emerging markets.
- **Operating profit:** Higher gross profit led to a substantial ¥10.6 billion increase, pushing up operating profit to a historic high.
 - ✓ **Forex impact** Net sales: +¥12.82 billion; SG&A expenses: +¥3.57 billion; operating profit: +¥5.64 billion
 - ✓ **At forex rates prevailing one year earlier:** Net sales + 8.0%; SG&A expenses: +9.9%; operating profit: +14.9%
- **Profit attributable to owners of the parent:** +17.2%
Foreign exchange loss (gain): Loss of ¥4.03 billion (decreased ¥5.3 billion year on year)



	First six months of fiscal year ending March 31, 2025	First six months of fiscal year ended March 31, 2024
1USD	¥152.6	¥141.0
1EUR	¥166.0	¥153.4
1CNY	¥21.2	¥19.8

Breakdown of Net Sales (By Business and Field)

Net Sales by Business and Field



The impact of the XR-Series and higher sales in emerging markets led to substantial increases in the hematology field. Also, sales grew in the hemostasis and immunochemistry fields, pushing up overall net sales.

(Billions of yen)

	First six months of fiscal year ending March 31, 2025		YoY (Previous year = 100%)	
	Results	Ratio	Yen basis	Excluding FX impact
Net sales	242.4	100.0%	114.0%	108.0%
Hematology	148.5	61.3%	115.9%	109.4%
FCM	1.5	0.7%	109.5%	103.0%
Urinalysis	19.5	8.1%	108.2%	102.0%
Hemostasis	36.7	15.2%	113.4%	108.1%
Immunochemistry	11.7	4.8%	111.8%	108.1%
Clinical chemistry	1.7	0.7%	114.5%	110.9%
Life science	10.5	4.4%	103.6%	98.4%
Others	10.2	4.2%	111.2%	105.2%
Diagnostics business	240.7	99.3%	113.8%	107.7%
Medical robotics business	1.7	0.7%	152.5%	152.5%

Tests related to COVID-19 (Included in life science, immunochemistry)

1H FY03/2025: ¥1.07 billion (sales in Japan only)

(Reference) 1H FY03/2024: ¥1.29 billion (sales in Japan only)

Breakdown of Net Sales (By Destination and Product Type)



Continued double-digit growth in reagent sales pushed up growth for the Group.


(Billions of yen)	First six months of fiscal year ending March 31, 2025		YoY (Previous year = 100%)	
	Results	Ratio	Yen basis	Local currency basis
Net sales	242.4	100.0%	114.0%	108.0%*
Americas	63.7	26.3%	111.4%	103.1%
EMEA	69.1	28.5%	116.0%	107.2%
China	54.5	22.5%	114.8%	108.0%
AP	24.7	10.2%	119.5%	114.3%*
Japan	30.3	12.5%	109.6%	-
Instruments	47.5	19.6%	100.9%	95.4%*
Reagents	150.7	62.2%	117.1%	111.2%*
Services	33.3	13.8%	114.0%	107.0%*
Other	10.8	4.5%	141.8%	135.4%*

*Year-on-year increase on a yen basis, excluding the impact of exchange rate fluctuations


Major Reasons for Changes, by Destination

Americas	<ul style="list-style-type: none"> Sales rose, pushed up by higher reagent in the hematology and urinalysis fields. In addition, we began selling reagents in the hemostasis fields.
EMEA	<ul style="list-style-type: none"> Sales increased. Due to a transition to direct sales and the impact of an OEM agreement in the hemostasis field, we saw double-digit reagent growth, centered on the hematology and hemostasis field.
China	<ul style="list-style-type: none"> Sales grew, bolstered by double-digit growth in the hematology field and increases in the hemostasis field.
AP	<ul style="list-style-type: none"> Strong demand in each country lead to favorable growth, leading to double-digit growth in all fields and pushing up sales.
Japan	<ul style="list-style-type: none"> Sales expanded. In the diagnostics business, performance was favorable in the hematology, hemostasis, and immunochemistry fields. Sales also rose in the medical robotics business.

By Destination



By Product Type



Information by Destination (Americas)



(Million USD)	First six months of fiscal year ending March 31, 2025	First six months of fiscal year ended March 31, 2024	YoY (Previous period = 100%)	
			Local currency basis	Yen basis
Net sales	417.8	405.4	103.1%	111.4%
Instruments	88.9	108.0	82.3%	89.0%
Reagents	212.3	191.7	110.7%	119.7%
Services, others	116.5	105.6	110.3%	119.4%

Although instrument sales dipped temporarily, an increase in the installed instrument base led to double-digit sales growth for reagents, pushing up sales for the region.


● Instruments

- ✓ Sales were down year on year, reflecting a large tender in the urinalysis field in the previous fiscal year and a delay in the timing of deliveries in the hematology field in North America, although orders remained positive. Sales in Brazil also continued to grow, so we expect a recovery in the second half of the fiscal year.

● Reagents

- ✓ An increase in the installed instrument base in the hematology and urinalysis fields led to double-digit growth, pushing up reagent sales.
- ✓ Hemostasis reagents increased. Sales of amyloid β testing reagents* were also firm.


*2.2 Million USD



Information by Destination (EMEA)

(Million EUR)	First six months of fiscal year ending March 31, 2025	First six months of fiscal year ended March 31, 2024	YoY (Previous period = 100%)	
			Local currency basis	Yen basis
Net sales	416.5	388.4	107.2%	116.0%
Instruments	91.9	96.6	95.1%	102.5%
Reagents	260.8	230.2	113.3%	122.7%
Services, others	63.6	61.4	103.6%	112.3%

Sales increased, as double-digit growth from reagent sales in the hematology, urinalysis and hemostasis fields, compensated for lower instrument sales.



Note: Sales to Russia are excluded, for past fiscal years, as well.

● Instruments

- ✓ Sales of the XR-Series led to favorable sales in the hematology field, and sales in the hemostasis field rose due to the impact of an OEM agreement. However, due to the switch to direct sales in Italy, lower sales temporarily in the urinalysis fields caused overall instrument sales to decline.

● Reagents

- ✓ In the hematology field, sales were favorable, thanks in part to a transition to direct sales in Saudi Arabia.
- ✓ Owing to an increase in the installed instrument base, sales in the urinalysis field were up in Spain and other locations. Also, the impact of an OEM agreement boosted sales in the hemostasis field, prompting higher reagent sales.

Information by Destination (China)

(Million CNY)	First six months of fiscal year ending March 31, 2025	First six months of fiscal year ended March 31, 2024	YoY (Previous period = 100%)	
			Local currency basis	Yen basis
Net sales	2,590.8	2,399.1	108.0%	114.8%
Instruments	344.6	394.3	87.4%	92.6%
Reagents	1,894.0	1,747.0	108.4%	115.4%
Services, others	352.0	257.6	136.6%	144.7%

Instrument sales were down, partly because of the impact of Q1 performance. Even so, solid reagent sales centered on the hematology field lifted sales for the region.


● Instruments

- ✓ Sales of locally manufactured products rose significantly for low-end products in the hematology field (XN™-L Series) and the urinalysis field.
- ✓ In Q2, sales entered a recovery phase in the hemostasis field, as we began selling locally manufactured products. Additionally, we have completed the approval for locally produced HISCL™ products in the immunochemistry field, and we expect a recovery in the second half of the fiscal year.

● Reagents


- ✓ In addition to an increase in the number of Tier 3 hospitals and more people undergoing screening, the installed instrument base also grew, leading to higher sales in the hematology and hemostasis fields and boosting overall reagent sales.

Sales (Million CNY)



Status of the IVD Market in China

Sales of hematology reagents increased due to a high share of the market for tier 3 hospitals and an increase in the number of outpatients.
 We grew sales for products in the low-end market and expanded the product portfolio.



Government procurement policies

- ✓ Increase number of locally manufactured instruments

Centralized purchasing

- ✓ Shift to direct sales and services
- ✓ Reduce the cost of sales ratio by internalizing reagent production

Anti-corruption movement

- ✓ A healthier market environment is advantageous for our company

Optimization of medical service prices (DRG/DIP)*

- ✓ A negligible impact in hematology
- ✓ Responding by transitioning to direct sales and lowering costs


*Introduced in 2010 as one of the driving forces behind the reform of the medical insurance payment system

Information by Destination (AP)

Note: Data changed to include sales in Russia.

(Billions of yen)	First six months of fiscal year ending March 31, 2025	First six months of fiscal year ended March 31, 2024	YoY (Previous period = 100%) Yen basis
Net sales	24.7	20.7	119.5% (114.3%)
Instruments	5.0	4.5	111.5%
Reagents	16.8	13.8	121.8%
Services, others	2.7	2.3	121.5%

Note: Figures in parentheses exclude the impact of exchange rate fluctuations.



As investment in the healthcare infrastructure continued, performance was favorable for instruments, reagents, and services, lifting sales by double digits. In addition, sales in India increased 35% year on year.

● Instruments

- ✓ Sales rose in the hematology field, centered on Australia and Thailand.
- ✓ Sales rose in the urinalysis field due to the acquisition of large-scale tenders in India. The hemostasis field was also favorable centered in Thailand and other parts of Southeast Asia.

● Reagents

- ✓ Sales in the hematology field were up significantly, as an increase in the installed instrument base pushed up sales in India, Indonesia, and the Philippines.
- ✓ An increase in the installed instrument base led to favorable sales in the immunochemistry field, and sales were up across all fields.

Information by Destination (Japan)

(Billions of yen)	First six months of fiscal year ending March 31, 2025	First six months of fiscal year ended March 31, 2024	YoY (Previous period = 100%) Yen basis
Net sales	30.3	27.6	109.6%
Diagnostics business	28.6	26.5	107.8%
Instruments	5.7	4.0	140.9%
Reagents	18.2	17.8	102.2%
Services, others	4.6	4.6	100.2%
Medical robotics business	1.7	1.1	152.5%

In the diagnostics field, sales of hematology instruments increased, as did sales of hemostasis and immunochemistry reagents. Sales in the medical robotics business were also favorable, leading to a double-digit sales increase.

Diagnostics business

● Instruments


- ✓ In the hematology field, sales of the XR series performed well, resulting in a significant sales increase of 98% year on year.

● Reagents

- ✓ Sales grew, due to the adoption of additional parameters in the hemostasis field, and an increase in the installed instrument base and the adoption of additional parameters in the immunochemistry field.


Medical robotics business

- ✓ Three units were installed in Q2, bringing the total for the first six months to nine units and raising the cumulative total to 64.
- ✓ Sales of services and consumables (such as forceps) rose, in line with the increase installed units and the number of cases.



Breakdown of Operating Profit

Note: Figures and comments below exclude the impact of exchange rates.



- Increased gross profit on higher sales: +¥8.85 billion
 - Impact of change in the cost of sales ratio: +¥2.25 billion (1.0pt improvement)
 - ✓ Positive factors: product mix, 1.1pt; improved cost of sales on products, etc., 0.4pt
 - ✓ Negative factors: service costs, 0.2pt; transportation expenses, 0.3pt
 - Higher SG&A expenses: -¥4.48 billion
 - ✓ Labor costs rose approx. ¥3.2 billion, due to personnel increases in response to an increase in scale and higher unit costs.
 - ✓ Other costs rose approx. ¥0.9 billion in line with an increase in scale and sales promotion activities.
 - Higher expenses related to internal digitalization: -¥1.72 billion
 - Higher R&D expenses: -¥0.22 billion
 - ✓ Ongoing investments in product development and costs related to regulatory affairs were higher.
 - Change in other operating income (expense): ¥0.36 billion
-
- FX impact: +¥5.64 billion


Breakdown of Changes in the Consolidated Statement of Financial Position



Assets: Although cash and cash equivalents increased, trade and other receivables declined due to the collection of trade receivables.
Liabilities: Current liabilities fell, owing to payments of expenses related to digitalization, etc.
Equity: The foreign exchange impact reduced net assets of local subsidiaries, but retained earnings increased.


Assets

Current assets: **-¥0.9 billion** (Billions of yen)
 Non-current assets: **+¥0.09 billion**




Liabilities/Equity

Liabilities: **-¥9.6 billion** (Billions of yen)
 Equity: **+¥8.8 billion**



Consolidated Cash Flows

Operating cash flows: Operating cash flows increased, owing to higher profit before tax and the collection of trade receivables.
 Investing cash flows: Investing cash flows were flat year on year. We invested in internal digitalization and the established bases in emerging markets.



Reference: News Releases and Topics (July–October 2024)

Reinforcement of Existing Businesses

- Sysmex Group's Largest Manufacturing Base Completed in India (AP)
- Sysmex Expands Strategic Alliance Agreement with QIAGEN in the Field of Genetic Testing
- Sysmex Applies for Manufacturing and Marketing Approval of an Assay Kit to Predict the Risk of Adverse Reactions from Anti-amyloid β Antibody Drugs for Alzheimer's Disease (Japan)
- Sysmex Launches "HISCL™ HIT IgG Assay Kit" Contributing to the Detection of Adverse Reactions to Heparin Therapy (Japan)

Expansion of New Businesses

- Medicaroid Receives Regulatory Approval in Malaysia for the hinotori™ Surgical Robot System (AP)

Sustainability

- Sysmex Approved by the Science Based Targets initiative
- Sysmex Corporation Selected as a Constituent of All ESG Indices Adopted by the GPIF

3.

Growth Strategy Progress and Initiatives


Emerging Market Strategies, Reinforcement of Existing Businesses,
Expansion of New Businesses

Emerging Market Strategies

Double-digit growth, capturing market growth and continuing high growth
Active sales promotion activities including trade shows in each region

Sales in India

(Billion JPY)



- The new production base in India: Preparations are processing smoothly




- Scientific Seminar in India: Thousands of participants, including online



Sales in Brazil

(Million USD)




- Trade shows in Brazil and Chile



Sales in META*

(Million EUR)



- Trade show in Saudi Arabia (Blood-Science)



*META: Middle East, Turkey, and Africa

Reinforcement of Existing Businesses

Hematology Field

The XR-Series is off to a good start in each region, and we plan to begin a rollout into the Americas next fiscal year.

Japan: Sales up 98% year on year, owing partly to strong demand for switching from the XE/XN™-Series, overwhelming presence
AP: Started sales promotion in Australia, Thailand, Malaysia, and Indonesia, and installation is progressing
EMEA, China: Steady installation since sales launch in April, sales volume up every quarter



XR-Series multiparameter
automated hematology analyzer

Immunochemistry Field

We advanced initiatives tailored to regional characteristics, such as Alzheimer's disease testing, and also promoted collaboration with Fujirebio HD

China: Obtained approval for locally manufactured products, HISCL-Series, earlier than planned, on track for shipment by the end of this fiscal year
AP: Achieved double-digit growth in both instruments and reagents due to the development of unique testing parameters
Japan: Sales increased due to expanded adoption of parameters to test for myocardial infarction and hepatitis.



HISCL-5000 automated
immunoassay system

Life science

Promoting strategic alliance agreement with QIAGEN in the genetic testing fields



Reinforcement of Existing Businesses

Hemostasis field

Entering a new stage of growth in the North America and EMEA, thanks in part to OEM agreement
Continuous growth is also expected in Japan, China, and AP through various initiatives.

EMEA: Sales increased 20% year on year, with higher sales of both instruments and reagents due to steady customer acquisition

Americas: Sales expected to grow in the second half of the year, with the start of successful tenders

China: Recovery in demand of instruments due to the launch of locally manufactured products (CN™-Series)

Japan: High expectations for integrated hematology and hemostasis instruments, and good trade show reception

AP: Continued double-digit growth due to rapid organic growth and expanded adoption of new parameters

■ Trade show in Japan (Blood-Science)



Expansion of New Businesses (Medical Robotics Business)




In Japan performance remains favorable and we are making steady progress on efforts to enter overseas markets.

● Status of hinotori installation

- ✓ We are making steady progress in introduction at university hospitals and flagship hospitals nationwide, establishing a foundation for introduction to affiliated hospitals and general hospitals.


64
units




● Overseas development plans

- ✓ Fiscal year ended March 31, 2024: Received approval in Singapore
- ✓ Fiscal year ending March 31, 2025: Obtained regulatory approval in Malaysia (August 2024), aiming to apply for regulatory approval in Europe
- ✓ Fiscal year ending March 31, 2026: Enter European market, obtain FDA regulatory approval
- ✓ Fiscal year ending March 31, 2027: Begin introduction in US market

Units installed to date



Surgeries performed in Japan



4.

**Financial Forecast for the
Fiscal Year Ending March 31, 2025**

Revised Earnings Forecast for the Fiscal Year Ending March 31, 2025



Note: Figures in green have been revised subsequent to our announcement at the start of the fiscal year (May 2024).

Owing to an improved cost of sales ratio,
we have raised our full-year operating profit forecast by ¥3.0 billion, compared with our initial forecast.

(Billions of yen)	1H of fiscal year ending March 31, 2025 (April–September)			2H of fiscal year ending March 31, 2025 (October–March)		Fiscal year ending March 31, 2025 (April–March)			
	Results	Ratio	Vs. plan	Revised forecast	Ratio	Revised forecast	Ratio	YoY (Previous period = 100%)	Vs. initial forecast
Net sales	242.4	100.0%	102.3%	267.6	100.0%	510.0	100.0%	110.5%	±0.0
Cost of sales	111.1	45.9%	-	124.9	46.7%	236.0	46.3%	107.8%	-1.0
SG&A expenses	72.3	29.8%	-	78.6	29.4%	150.9	29.6%	112.9%	-1.0
R&D expenses	15.2	6.3%	-	18.8	7.0%	34.0	6.7%	108.3%	-1.0
Other income (expenses)	0.8	0.3%	-	0.1	-	0.9	0.2%	82.9%	±0.0
Operating profit	44.5	18.4%	120.3%	45.5	17.0%	90.0	17.6%	114.9%	+3.0
Planned investment	Capital expenditure: ¥50.0 billion		Depreciation and amortization: ¥40.0 billion						

● Assumed Exchange Rates

	Full year (Announced May 2024)	Full year (Revised November 2024)	Second half (Unchanged from May 2024)
1 USD	¥147.0	¥149.8	¥147.0
1 EUR	¥158.0	¥162.0	¥158.0
1 CNY	¥20.4	¥20.8	¥20.4

● Exchange Rate Sensitivity (Year)

	Net sales	Operating profit
USD	¥0.80 billion	¥0.14 billion
EUR	¥0.55 billion	¥0.10 billion
CNY	¥5.75 billion	¥4.21 billion

Dividend Forecast

- The dividend amount, an increase, remains unchanged from our initial forecast at the start of the year.

	Interim dividend	Year-end dividend	Total	Payout ratio
Fiscal year ended March 31, 2024	¥42	¥42	¥84	35.4%
Fiscal year ending March 31, 2025 (proposal) <small>Note: Three-for-one stock split on April 1, 2024</small>	¥15	¥15	¥30	34.3%

Note: The Company conducted a three-for-one stock split of common stock on April 1, 2024. The actual dividend amount before the stock split is shown for the fiscal year ended March 31, 2024.

Sysmex aims to maintain a proper balance between aggressive investment, which is designed to sustain steady high growth, and returns to our shareholders as our earning power increases. In terms of returns to shareholders, we intend to provide a stable dividend on a continuous basis and aim for a consolidated payout ratio of 30% under our basic policy of sharing the successes of our operations in line with business performance.

Change from a three-year plan with two years rolling to a three-year fixed-period plan

Reasons for the change

- We are promoting various measures based on the mid-term management plan in order to realize the long-term corporate strategy we developed by backcasting from our desired future state in fiscal 2033.
- Fixing the period at three years will clarify the status of target achievement, enhance the effectiveness of our strategy, facilitate smooth dialogue with shareholders and investors, and clarify the Company's responsibilities.
- Detailed target figures for next fiscal year, the final year of the mid-term management plan (third year), will be provided at the announcement of financial results in May 2025, taking into account external factors such as foreign exchange rates and progress made during the current fiscal year.

(Appendix)

Q2 Business Results (Year on Year)



Growth in all regions led to double-digit growth in net sales and profits.

	Q2 of fiscal year ending March 31, 2025 (July to September)			Q2 of fiscal year ended March 31, 2024 (July to September)	
	Results	Ratio	YoY (Previous period = 100%)	Results	Ratio
Net sales	130.5	100.0%	111.2%	117.3	100.0%
Cost of sales	59.2	45.4%	104.5%	56.7	48.4%
SG&A expenses	36.3	27.9%	112.1%	32.4	27.6%
R&D expenses	7.8	6.0%	0.0%	7.8	6.7%
Other operating income (expenses)	0.7	0.6%	278.6%	0.2	0.2%
Operating profit	27.7	21.3%	135.1%	20.5	17.5%
Profit attributable to owners of the parent	14.9	11.5%	110.4%	13.5	11.6%

(Billions of yen)

Sales Forecast for the Fiscal Year Ending March 31, 2025 (By Business, Field and Destination)



Sales by business and field

(Billions of yen)

	FY03/2025	YoY growth rate
Hematology	303.0	+10.2%
FCM	5.0	+50.7%
Urinalysis	42.5	+8.9%
Hemostasis	82.5	+13.1%
Immunochemistry	25.0	+5.7%
Clinical chemistry	3.5	+3.6%
Life science	21.5	+ 4.8%
Others	21.0	+ 4.8%
Diagnostics business	504.0	+ 10.1%
Medical robotics business	6.0	+ 60.2%
Total	510.0	+10.5%

Sales by destination

(Billions of yen)

	FY03/2025	YoY growth rate
Japan	6.70	+7.9%
Americas	128.5	+8.2%
EMEA	140.5	+12.1%
China	120.0	+9.1%
Asia Pacific	5.40	+19.4%

Note: Changes are in green.

Publication of the *Sysmex Report 2024* and the *Sysmex Sustainability Data Book 2024*






Sysmex Report 2024 (integrated report)

<https://www.sysmex.co.jp/en/ir/library/annual-reports/index.html>

Sysmex Sustainability Data Book 2024 (yearly report)

<https://www.sysmex.co.jp/en/csr/report/index.html>



Sustainability Measure	Units	Description	2023				2022				Progress and Status
			Actual	Target	Actual	Target	Actual	Target			
Carbon Footprint (Scope 1 & 2)	tCO ₂ e	Production facilities	1,143	1,485	1,480	1,832	1,368	1,700	1,368	1,700	On track
		Business travel	306	287	296	257	200	200	200	200	On track
		Energy consumption	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	On track
		Water consumption	46	54	54	52	52	52	52	52	On track
		Waste management	122.0	130.0	130.0	130.0	130.0	130.0	130.0	130.0	On track
		Greenhouse gas emissions	4	2	2	2	2	2	2	2	On track
		Energy efficiency	0	0	0	0	0	0	0	0	On track
		Renewable energy	85%	89%	90%	94%	90%	94%	90%	94%	On track
		Waste recycling	2	5	5	4	5	5	5	5	On track
		Waste reduction	85%	85%	85%	85%	85%	85%	85%	85%	On track

Together for a better
healthcare journey